Overview
Biomedica is a European specialty pharmaceutical company with a representative office in Boston. The company commercializes high-value rare and ultra-rare therapies across more than 30 markets in Central and Eastern Europe, the CIS, Russia, Türkiye, Israel, and selected MENA countries.
What makes Biomedica different?
Biomedica does more than distribute products—it builds markets and identifies patients. Its experienced medical teams, approximately 30% of whom are physicians or PhD-level professionals, work closely with KOLs, patient advocacy groups, healthcare authorities, and payers to expand screening, accelerate diagnosis, establish treatment pathways, and secure dedicated funding for innovative therapies.
With more than $120 million in revenue, nearly 15 product launches since 2019, and a proven track record supporting publicly traded US and European biotechnology companies, Biomedica provides compliant, end-to-end commercialization through its own local teams and infrastructure—all under a single EU contract. Its capabilities include medical affairs, market access, regulatory support, quality, pharmacovigilance, supply chain, distribution, and commercial operations, including direct access to complex markets such as Russia.
For some partners, Biomedica’s territories have become their second-largest source of revenue after the United States, while requiring minimal operational involvement from their US-based teams.
Why engage 6–12 months before FDA approval?
Early engagement enables market assessment, KOL and treatment-centre mapping, patient identification, access planning, and operational readiness to begin well ahead of approval.
Where legally permitted, a compliant Named Patient Program can be launched in parallel with – or shortly after – a US launch. This may provide earlier access for eligible patients, generate initial ex-US revenue, and support greater pricing flexibility before lower public reimbursement benchmarks emerge in major European markets. Depending on the applicable country framework, NPP transactions may also allow pricing and commercial terms to remain confidential.
Biomedica welcomes introductory discussions with biotechnology companies seeking to accelerate ex-US commercialization through exclusive distribution, in-licensing, or hybrid partnership models.
For all Business Development inquiries, please contact bd@biomedica.bio.